Autoimmune Pancreatitis Type 2: Case Report

Chidinma Onweni, MD¹, Harika Balagoni, MD¹, Jennifer M. Treece, MD, MBA¹, Emmanuel Addo Yobo, MD¹, Archi Patel, MD¹, Jennifer Phemister, MD¹,², Manoj Srinath, MD¹,², and Mark F. Young, MD¹,²

Abstract
A middle-aged man presents with acute pancreatitis of unknown etiology and is found to have a presentation consistent with the diagnosis of type 2 autoimmune pancreatitis (AIP). AIP is a group of rare heterogeneous diseases that are challenging to diagnose. There are 2 types of AIP. Type 1 disease is the more common worldwide than type 2 AIP. While type 1 AIP is associated with IgG4-positive antibodies, type 2 AIP is IgG4 antibody negative. Both types of AIP are responsive to corticosteroid treatment. Although type 1 AIP has more extrapancreatic manifestations and more commonly relapses, this is a case of a patient with type 2 AIP with inflammatory bowel disease and relapsing course.

Keywords
autoimmune pancreatitis, type 1, type 2, corticosteroid therapy, IgG4 antibody, IgG4-related disease, chronic pancreatitis, lymphoplasmacytic sclerosing pancreatitis

Case Report
We report a case of a 64-year-old male patient who presented with acute pancreatitis. The patient’s history of present illness, past medical history, recent social history, right upper quadrant ultrasonography, and hepatitis panel were all nonsuggestive of an etiology for the patient’s acute pancreatitis. Of note, the patient admitted to a remote smoking history, remote heavy drinking as a teenager, and denied illicit drug use. Magnetic resonance cholangiopancreatography showed dilated intrahepatic and extrahepatic bile ducts and a distal common bile duct (CBD) stricture with a moderately enlarged head of the pancreas. Laboratory studies collected during the hospital admission were negative for anti-mitochondrial antibody, negative for anti-smooth muscle antibody, negative for immunoglobulin G (IgG) subclasses, antinuclear antibody (ANA) was negative, and the hepatitis panel was also negative. The patient’s symptoms improved gradually, so the patient was discharged home without a definitive diagnosis for the underlying etiology of his acute pancreatitis. A few days following hospital discharge home, the patient reported new onset of persistent diarrhea. Initial fixed sigmoidoscopy showed circumferential lesion suggesting a diagnosis of ulcerative colitis. A subsequent colonoscopy showed skipped lesions suggesting a diagnosis of Crohn’s disease. The ileum was not involved but rectum was involved. Because the patient’s colon lesion and histological evaluation suggested both ulcerative colitis and Crohn’s disease, the diagnosis of indeterminate colitis was determined as neither was completely met (see Figure 1).

A few weeks later, he underwent an endoscopic ultrasound (EUS), which showed a pancreatic head mass. Core biopsy of the pancreatic mass revealed benign glandular cells, rare mildly atypical ductal cells, few plasma cells, few inflammatory cells, and stains for immunoglobulin G (IgG) and CD138 demonstrated nonspecific staining, which were inconclusive. CD138 is known to be a plasma cell marker, but pancreatic acinar cells in chronic pancreatitis also express CD138. Background debris with no malignant cells was also identified. The patient was treated with intravenous (IV)
corticosteroids with a slow taper of oral corticosteroids over several months. After completing the corticosteroid course, a repeated EUS was done approximately 6 months following the first EUS, which was normal with no evidence of a dilated CBD; the pancreatic head parenchyma appeared normal and there was no evidence of a focal mass lesion or progression. This implies that the patient’s pancreatitis was responsive to corticosteroids, which indicates a diagnosis of an autoimmune cause. Type 2 AIP was diagnosed as this patient’s pancreatitis was IgG4 negative, associated with inflammatory bowel disease, and is associated with mass in the head of the pancreas, which was also present in this patient before treatment with corticosteroids.

Since his initial diagnosis of type 2 AIP, the patient has had multiple recurrences of diarrhea and some recurrence pancreatitis following cessation of corticosteroid use. He was evaluated by multiple experts at several facilities, who recommended focusing treatment on the patient’s indeterminate colitis with immunomodulators. The patient was initially started on adalimumab (Humira) with improvement of colitis and control of recurrent (one episode of recurrent) acute pancreatitis, which allowed for tapering the patient off the chronic corticosteroids. His diarrhea later returned, and he was found to have elevated antibodies to adalimumab, so adalimumab was discontinued and vedolizumab has been started, which is currently controlling the patient’s symptoms.

**Epidemiology**

Autoimmune pancreatitis is a group of rare heterogeneous diseases. There are 2 types of AIP. Type 1 disease is the more common worldwide than type 2 AIP. Type 1 AIP is more common in men and occurs in patients that are approximately 60 years older, and type 2 AIP presents in patients that are 40 to 50 years old and occurs at the same frequency in males and females.

**Pathology**

Type 1 AIP is associated with elevated levels of IgG4-positive cells and extrapancreatic manifestations. The histology of both type 1 and type 2 AIP includes periductal lymphoplasmacytic infiltrate and storiform fibrosis, but type 2 also has granulocytic epithelial lesion duct change. The pancreatic histology of type 1 AIP is known as lymphoplasmacytic sclerosing pancreatitis with obliterator phlebitis but without predominant neutrophilic infiltrate in the lobule and duct. In type 2 AIP, IgG4-positive cells are uncommon, IgG is normal, predominant neutrophilic infiltrate in the lobule and duct are present, and it is more difficult to diagnose than Type 1 AIP (see Table 1).

The HISORt diagnostic criteria for diagnosing type 1 AIP is shown in Table 2. HISORt stands for histology, pancreatic imaging, serology, other organ involvement, and response to therapy.

**Clinical Presentation and Diagnosis**

Both types of AIP can present with obstructive jaundice and weight loss. Type 2 AIP more commonly presents with obstructive jaundice, abdominal pain, weight loss, and acute pancreatitis. Patients with AIP present with chronic pancreatitis of unknown etiology. Extensive evaluation for underlying etiology of pancreatitis is indeterminate. AIP is seldom encountered and is not a definitive diagnosis. Therefore, some investigators have suggested using a combination of laboratory testing, imaging, histological findings, association to other autoimmune disease, and response to corticosteroid treatment to establish the diagnosis. Type 1 AIP can be diagnosed through imaging and serological markers positive for IgG4 autoantibodies. Type 2 AIP requires core needle biopsy to diagnose through localizing the granulocytic epithelial lesion of the pancreatic duct.

**Treatment**

AIP is responsive to corticosteroid use in the acute setting, but relapse is common following cessation of corticosteroid use. Recurrence is more common in type 1 AIP but can occur in type 2 AIP. Immunomodulators are effective in maintaining remission. For the patient presented in this case, the patient took repeated courses of corticosteroid with recurrence of symptoms on cessation of corticosteroid treatment. An expert at a prestigious university hospital recommended that the
The patient's treatment be directed toward colitis with biologic therapy as it was thought that biologic may also provide benefit to AIP. The patient was started on Humira and was tapered off prednisone. Six months later, the patient was experiencing abdominal pain and diarrhea, stool studies were positive for *Clostridium difficile*. At that time Humira drug levels and antibody levels were drawn, which showed elevated antibody levels. The patient completed a course of metronidazole with resolution of symptoms. The patient was previously on azathioprine but developed hepatotoxicity with liver function tests and returned to normal after medication discontinuation.

**Discussion**

The purpose of this case report is to review the limited knowledge that exists about AIP, particularly type 2 AIP, which is rarer than type 1 AIP, and to discuss how AIP presents clinically with methods to diagnosis this elusive
disease. Type 1 AIP is the variant of AIP that has been described and studied more extensively as it is more common than type 2 AIP. The current diagnostic criteria focus on diagnosing type 1 AIP without assessing for type 2 AIP. From this case, we learned that there is limited knowledge about the diagnosis of type 2 AIP. The diagnosis is unclear even following biopsy of the pancreas. As seen in this patient, the biopsy of the pancreatic mass only revealed benign glandular cells and background debris with no malignant cells identified. The diagnosis was presumed to be type 2 AIP due to IgG4 being negative, the patient responded to corticosteroid treatment with improvement of symptoms, and the resolution of the dilated intrahepatic and extrahepatic bile ducts, the distal CBD stricture, and the mass at the head of the pancreas following corticosteroid use. Of note, the sensitivity of serum IgG4 ranges from 53% to 95%, so having a negative IgG4 level does not exclude type 1 AIP. It is interesting to note that type 1 AIP is associated with biliary findings, primarily primary sclerosing cholangitis. Type 2 AIP principally affects the pancreas, with only one third having extrapancreatic magnifications, such as inflammatory bowel disease like ulcerative colitis. Our patient, interestingly, fits into the one third of type 2 AIP cases with extrapancreatic findings as he developed persistent diarrhea. He was diagnosed with colitis, and the type of colitis was unclear via biopsy. The gastroenterologist diagnosed him as presumptive ulcerative colitis.

Conclusion
AIP is a rare disease with type 2 AIP being rarer than type 1 AIP. Diagnosing AIP is challenging as even a core needle biopsy of a pancreatic mass is not useful in diagnosing AIP. AIP remains a rare disease and little is known about the diagnosis or underlying etiology, especially in type 2 AIP. Type 1 AIP has IgG4-positive antibodies. As relapse is very common following cessation of corticosteroid use treatment, immunomodulators are needed to maintain remission for both type 1 and type 2 AIP.

Authors’ Note
The patient whose case is described in this article has been managed by the medicine team and has been seen at the East Tennessee State University–affiliated teaching hospital.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval
Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent
Written informed consent was obtained from the patient for their anonymized information to be published in this article.

References
1. Takita M, Itoh T, Matsumoto S, et al. Autoimmune chronic pancreatitis with IgG4-related pancreatic pseudocyst in a patient undergoing total pancreatectomy followed by autologous islet transplantation: a case report. Pancreas. 2013;42:175-177. doi:10.1097/MPA.0b013e3182546e37.
2. Sugumar A, Chari S. Autoimmune pancreatitis: an update. Expert Rev Gastroenterol Hepatol. 2009;3:197-204.
3. Ketwaroo GA, Sheth S. Autoimmune pancreatitis. Gastroenterol Rep (Oxf). 2013;1:27-32. doi:10.1093/gastro/got011.
4. Detlefsen S, Löh M, Drewe AM, Frokjaer JB, Klöppel G. Current concepts in the diagnosis and treatment of type 1 and type 2 autoimmune pancreatitis. Recent Pat Inflamm Allergy Drug Discov. 2011;5:136-149.
5. Notohara K, Nishimori I, Mizuno N, et al. Clinicopathological features of type 2 autoimmune pancreatitis in Japan: results in a multicenter survey. Pancreas. 2015;44:1072-1077.
6. Sah RP, Chari ST. Recent developments in steroid-responsive pancreatitis (autoimmune pancreatitis). Curr Opin Gastroenterol. 2015;31:387-394. doi:10.1097/MOG.0000000000000205.
7. Okazaki K, Uchida K, Sumimoto K, Mitsuyama T, Ikeura T, Takaoka M. Autoimmune pancreatitis: pathogenesis, latest developments, and clinical guidance. Ther Adv Chronic Dis. 2014;5:104-111. doi:10.1177/2040622314527120.
8. Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62:1771-1776. doi:10.1136/gutjnl-2012-303617.
9. Gardner TB, Levy MJ, Takahashi N, Smyrk TC, Chari ST. Misdiagnosis of autoimmune pancreatitis: a caution to clinicians. Am J Gastroenterol. 2009;104:1620-1623. doi:10.1038/aig.2008.89.
10. Kamisawa T, Chari ST, Lerch MM, Kim MH, Gress TM, Shimosegawa T. Recent advances in autoimmune pancreatitis: type 1 and type 2. Gut. 2013;62:1373-1380.
11. Pieringer H, Parzer I, Wöhrer A, Reis P, Oppl B, Zwerina J. IgG4-related disease: an orphan disease with many faces. Orphanet J Rare Dis. 2014;9:110. doi:10.1186/s13023-014-0110-z.